Press Release from Research Diagnsotisc Inc
sCD27-A Novel Tumor Marker
CD27 is a transmembrane disullfide-linked glycoprotein found exclusively
on human T and B lymphocytes. It belongs to the TNFr receptor superfamily
for membrane bound and soluble cytokines, whose members are involved in cell
differentiation and survival. A soluble form of CD27 (sCD27) is released
into the supernatant of activated T-cells and found in serum and urine of
healthy individuals. Levels of sCD27 have been found to increase in patients
suffering from a variety of immunopathological diseases which suggests that
measurements of sCD27 can serve as a marker for T-cell activation.
A recent study published in March 1996 issue of Blood shows that measurement
of sCD27 is a new, acccurate and sensitive parameter for the diagnosis of
meningeal metastasis of lymphoid malignancies.
Children with ALL and NHL have a particular high risk of developing meningeal
localizations. Although all these children, even without clinical evidence,
are routinely examined for meningeal localization in CSF, they are nevertheless
undergoing central nervous system staging as precaution. To prevent this
often unnecessary treatment the sCD27 marker will be a very important diagnostic
Until now, diagnosis of meningeal localization depended upon cytological examination of cerebrospinal fluid (CSF) and could result in false negative rates of 40% during early meningeal involvement.Tthe value of additional immunocytology is limited because of its low sensitivity, while other tumor markers such as B2 microglobulin and TNF-alpha show a poor specificity.
The study comprised five patient group:
|Group||Patients||Samples||results sCD27 assay|
|I||50 controls||50||all negative|
|II||70 children (55 ALL, 15 NHL)||104||
45 patients suspected of meningeal
localization of ALL or NHL
4 patients with primary cerebral
7 positive whereas
cytology was negatove
32 patients with either myeloid
leukemia or solid tumors suspected
of meningeal metastasis
|40||1 sample positive|
The reuslts of the sCD27 assay were compared to cytology, combined with clinical follow-up and B2-microglobulin levels. (HIV seropositive patients were excluded).
Furthermore, it was shown that CSF-sCD27 discriminates excellently between meningeal and/or cerebral involvement by either a lymphoid malignancy or a soid tumor. It is also found to be a reliable marker for remission and relapse.
sCD27 is a diagnostic test in this study superior to B2 microglobulin levels.
1. Kersten MJ, EVers LM, Portegies P, Dellemijn PLI, von dem Borne AEGKR, van Lier RAW, van OERS MHJ,
ELEVATION OF CEREBROSPINAL FLUID SOLUBLE CD27 LEVELS IN PATIENTS WITH MENINGEAL LOCALIZATION OF LYMPHOID MALIGNANCIES, Blood Vol 87, no 5:pp 1985-1989, 1996.
The Pelikine-compact kit (manufactured by C:LB Reagents-a division of the Netherlands Red Cross) for measuring sCD27 is available through Research Diagnostics Inc for in vitro research use only-not for use in diagnostics or diagnostic procedures.
Please request the sCD27 kit insert, catalog#RDI-M1960clb
For additional antibodies against CD27 for use in flow cytometry, ELISA and hiostochemistry, see our antibody section CD27 antibodies.
RDI Divison of researchd Industries Intl
San Jose, 95123 CA Snell ave 658
phone (201) 584-7093